Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 3/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.44 |
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1517872 | 0.87 | ACE (0.49) | ACEALDH1A1SMN1; SMN2PREPFKBP1A | |
| SCHEMBL6786455 | 0.86 | ACE (0.52) | ACEALDH1A1SMN1; SMN2CPT2CPT1A | |
| SCHEMBL6786452 | 0.86 | ACE (0.52) | ACEALDH1A1SMN1; SMN2CPT2CPT1A | |
| SCHEMBL11419558 | 0.85 | ACE (0.53) | ACEALDH1A1SMN1; SMN2PREPFKBP1A | |
| SCHEMBL6789072 | 0.82 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CPT2CPT1A | |
| SCHEMBL6789083 | 0.82 | ACE (0.55) | ACEALDH1A1SMN1; SMN2CPT2CPT1A | |
| SCHEMBL29553 | 0.78 | PREP (0.67) | ALDH1A1SMN1; SMN2PREPKMT2A | |
| SCHEMBL475715 | 0.78 | PREP (0.67) | ALDH1A1SMN1; SMN2PREPKMT2A | |
| SCHEMBL29658848 | 0.78 | PREP (0.67) | ALDH1A1SMN1; SMN2PREPKMT2A | |
| SCHEMBL205223 | 0.78 | PREP (0.67) | ALDH1A1SMN1; SMN2PREPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | ACE 2424/4885ALDH1A1 574/4885SMN1; SMN2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.